Program
BT-114143
A development code. Also written as “Low-dose BT-114143”, “BT-114143 Injection at low dose” and “BT-114143 Injection at Medium-dose”.
Its studies are mostly in Metrorrhagia, led by ScinnoHub Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ScinnoHub Pharmaceutical | 32 open or running | phase 2since Jul 18, 2025 | Jul 18, 2025 | Dec 31, 2026phase 2 · NCT07127042 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2025First study: phase 2 study in Total Knee ArthroplastyFirst studyNCT07127042 · 270 planned · China
- Aug 14, 20252 phase 1 studiesNCT07169214, NCT07169240
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Total Knee ArthroplastyNCT07127042
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07169240Healthy Subjects (HS) · China | 1 | Completed | Apr 17, 2024 | 84 |
| NCT07169214Metrorrhagia · China | 1 | Recruiting | Sep 23, 2025 | 39 |
| NCT07127042Total Knee Arthroplasty · China | 2 | Recruiting | Dec 31, 2026 | 270 |
How it is read
Names in the registry
- “BT-114143”, 11 entries
- “Low-dose BT-114143”, 1 entry
- “BT-114143 Injection at low dose”, 1 entry
- “BT-114143 Injection at Medium-dose”, 1 entry
- “BT-114143 Injection at High-dose”, 1 entry
Codes read as this program: BT114143.
Conditions, from the studies’ own filings
- Metrorrhagia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.